News | December 26, 2007

Canada Reactor Back in Business

December 27, 2007 - After a longer-than-expected maintenance shutdown, production of radioisotopes for molecular imaging and targeted therapy is back online at the National Research Universal (NRU) reactor in Chalk River, Ontario. The reactor was returned to service following direct intervention by the Canadian government, which in effect over-ruled the safety concerns of the Canadian Nuclear Safety Commission (CNSC).

The NRU entered a regularly scheduled maintenance shutdown on Nov. 18 (see A break in the supply chain on medicalphysicsweb). That shutdown resulted in an interruption in the supply of molybdenum-99 (Mo-99), a fission by-product that's used to make technetium-99m (Tc-99m) and iodine-131 (I-131). Tc-99m and I-131 are the predominant radionuclides used in diagnostic and therapeutic nuclear-medicine studies.

In early December, however, things started to get messy. Atomic Energy of Canada Limited (AECL), the government-owned company which runs the NRU reactor, announced an extension of the outage till early/mid-January to allow "modifications required for the installation of two new motor starters for the reactor cooling pump, and to connect the motors to an additional back-up power supply".

That announcement came against an already grim clinical backdrop, with thousands of seriously ill patients in North America facing delays to diagnostic procedures as a result of the disruption to isotope supply lines.

On Dec. 11, in response to concerns from the medical community, the Canadian parliament agreed a bill that temporarily suspended (for 120 days) the CNSC's oversight role, thus allowing the NRU to start up again even though it still did not fully meet safety standards.

The reactor was safely returned to service on Dec.16, which means that medical isotopes will by now be ready for removal, processing and distribution. In the coming weeks, AECL will complete the maintenance work during normal reactor operations.

The next time the NRU needs to be shut down for maintenance the AECL is likely to be better prepared. The agency has built two new reactors, MAPLE 1 and MAPLE 2, for exclusive production of medical isotopes. Originally scheduled to go online in 2004, they are now due to start up in October 2008 and October 2009, respectively.

• MDS Nordion (Ottawa, Canada), a leading supplier of medical isotopes, had reckoned it would take an $8-9 million earnings hit in its current quarter as a result of the NRU outage. With the reactor back online, however, the company anticipates less of a financial impact than previously estimated.

Source: Joe McEntee is editor of medicalphysicsweb. Additional reporting by physicsworld.com.

For more information: www.aecl.ca

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media| July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media| June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media| March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Technical University of Munich, Munich Compact Light Source, MuCLS, angiography, contrast agents

(a) Photograph of the sample in waterbath. (b) Empty image of full MuCLS beam. (c) Quasi-mono-energetic angiography image of a porcine heart acquired at the MuCLS, with iodine-based contrast agent injected into the left coronary artery. Visible are the left anterior descending artery (LAD) and the left circumflex artery (LCX). Image courtesy of the authors.

News | Angiography| March 10, 2017
The most prevalent method for obtaining images of clogged coronary vessels is coronary angiography. For some patients,...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media| January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init